Refractory immune thrombocytopenia (ITP) with suspected Evans syndrome requiring quadruple therapy
Abstract
Immune thrombocytopenia (ITP) is a common cause of acquired thrombocytopenia in children, second only to chemotherapy-induced thrombocytopenia.[1] Most patients respond well to first line therapies, however about there is a high rate of relapse in initially responsive patients.[2] We report a case of recurrent severe form of ITP who failed a re-trial of first line therapies and required second line treatments via a quadruple therapy of immunosuppressants. This case is not only unique due to the aggressive treatment required, but also because patient also had investigation results suggestive of autoimmune hemolytic anemia (AIHA) raising suspicion of Evans Syndrome.
References
2. Neunert CE. Management of newly diagnosed immune thrombocytopenia: can we change outcomes? Blood Adv 2017; 1(24): 2295–2301.
3. Kalfon S, Hamadeh H, Schachter Y, et al. Cutaneous hemorrhage types as supportive factors for predicting chronic immune thrombocytopenia in children. J Pediatr Hematol Oncol 2018; 40(5): 337-340.
4. Psaila B, Bussel JB. Refractory immune thrombocytopenic purpura: current strategies for investigation and management. Br J Haematol 2008; 143(1): 16-26.
5. Miano M. How I manage Evans Syndrome and AIHA cases in children. Br J Haematol 2015; 143(1): 16-26.
6. Aster, R. H., Curtis, B. R., McFarland, J. G., & Bougie, D. W. (2009). Drug‐induced immune thrombocytopenia: pathogenesis, diagnosis, and management. Journal of Thrombosis and Haemostasis, 7(6), 911-918.
7. Cines, D. B., Bussel, J. B., Liebman, H. A., & Luning Prak, E. T. (2009). The ITP syndrome: pathogenic and clinical diversity. Blood, 113(26), 6511-6521.
Copyright (c) 2020 Journal of Rare Diseases and Orphan Drugs
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
